Brittle tendons in mice reveal the potential downside of myostatin inhibitor drugs that are attracting interest as possible treatments for muscular dystrophy and as illicit performance-enhancing drugs for athletes. A new animal study raises doubts about one approach to treating muscular dystrophy.